AIM ImmunoTech Inc.
AMEXAIM ImmunoTech heads into its May 18 earnings date with short interest surging, borrowing costs punishingly high, and a Phase 3 trial announcement doing little to arrest a brutal month-long slide. Short positioning rebuilt aggressively this week. Short interest as a percentage of the free float jumped 62% over the past seven days to reach 9.1%, nearly doubling from the 5.6% level…
Snapshot as of 10 May 2026
AIM ImmunoTech heads into its May 18 earnings date with short interest surging, borrowing costs punishingly high, and a Phase 3 trial announcement doing little to arrest a brutal month-long slide. Short positioning…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AIM — free to start on ORTEX.
Sign up for free →Open AIM on ORTEX